申请人:Rhone-Poulenc Rorer Pharmaceuticals Inc.
公开号:US05561134A1
公开(公告)日:1996-10-01
Compounds of the Formula ##STR1## wherein: K is N or N.fwdarw.O; Q is CH.sub.2 or O; T is ##STR2## or R.sub.3 O--CH.sub.2 ; X is a straight or branched chain alkylene, cycloalkylene or cycloalkenylene group, each of which is optionally substituted by at least one CH.sub.3, CH.sub.3 CH.sub.2, Cl, F, CF.sub.3 or CH.sub.3 O; Y is NR.sub.4, O or S; a=0 or 1; Z is of the formula ##STR3## Z.sub.1 is N, CR.sub.5, (CH).sub.m --CR.sub.5 or (CH).sub.m --N, m being 1 or 2; Z.sub.2 is N, NR.sub.6, O or S, n being 0 or 1; R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are independently H, alkyl, aryl or heterocyclyl; R.sub.a and R.sub.b are independently H, OH, alkyl, hydroxyalkyl, alkyl mercaptyl, thioalkyl, alkoxy, alkyoxyalkyl, amino, alkyl amino, carboxyl, acyl, halogen, carbamoyl, alkyl carbamoyl, aryl or heterocyclyl; and R' and R" are independently hydrogen, alkyl, aralkyl, carbamoyl, alkyl carbamoyl, dialkylcarbamoyl, acyl, alkoxycarbonyl aralkoxycarbonyl, aryloxycarbonyl, or R' and R" together may form ##STR4## where R.sub.c is hydrogen or alkyl, ##STR5## where R.sub.d and R.sub.e are independently hydrogen, alkyl, or together with the carbon atom to which they are attached may form a 1,1-cycloalkyl group; provided that when X is straight chain alkylene and Q is oxygen, then Z represents a heterocyclyl including at least two heteroatoms, which are adenosine agonists useful as antihypertensive, cardioprotective, antiischemic, and antilipolytic agents, pharmaceutical compositions including such compounds, and their use in treating hypertension, myocardial ischemia, ameliorating ischemic injury and myocardial infarct size consequent to myocardial ischemia, hyperlipidemia and hypercholesterolemia are claimed.
该公式的化合物为##STR1##,其中:K为N或N.fwdarw.O; Q为CH.sub.2或O; T为##STR2##或R.sub.3 O--CH.sub.2; X为直链或支链烷基、环烷基或环烯基,每个基团可以选择性地被至少一个CH.sub.3、CH.sub.3 CH.sub.2、Cl、F、CF.sub.3或CH.sub.3 O取代; Y为NR.sub.4、O或S; a=0或1; Z的化学式为##STR3##Z.sub.1为N、CR.sub.5、(CH).sub.m --CR.sub.5或(CH).sub.m --N,其中m为1或2; Z.sub.2为N、NR.sub.6、O或S,其中n为0或1; R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5和R.sub.6独立地为H、烷基、芳基或杂环基; R.sub.a和R.sub.b独立地为H、OH、烷基、羟基烷基、烷基硫醇基、硫代烷基、烷氧基、烷氧烷基、氨基、烷基氨基、羧基、酰基、卤素、氨基甲酰基、芳基或杂环基; R'和R"独立地为氢、烷基、芳基烷基、氨基甲酰基、烷基氨基甲酰基、二烷基氨基甲酰基、酰基、烷氧羰基、芳基氧羰基,或R'和R"在一起可以形成##STR4##其中R.sub.c为氢或烷基,##STR5##其中R.sub.d和R.sub.e独立地为氢、烷基,或者与它们连接的碳原子一起可以形成1,1-环烷基; 前提是当X为直链烷基且Q为氧时,Z表示至少包含两个杂原子的杂环基,这些化合物是腺苷受体激动剂,可用作降压、心脏保护、抗缺血和抗脂解剂,包括这些化合物的制药组合物,以及它们用于治疗高血压、心肌缺血、改善因心肌缺血引起的缺血性损伤和心肌梗死大小、高脂血症和高胆固醇血症的用途。